- Home
- NOTE vs CHRS Comparison
NOTE vs CHRS Comparison
Compare NOTE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- CHRS
- Stock Information
- Founded
- NOTE 2013
- CHRS 2010
- Country
- NOTE United States
- CHRS United States
- Employees
- NOTE N/A
- CHRS N/A
- Industry
- NOTE EDP Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOTE Technology
- CHRS Health Care
- Exchange
- NOTE Nasdaq
- CHRS Nasdaq
- Market Cap
- NOTE 83.1M
- CHRS 84.2M
- IPO Year
- NOTE N/A
- CHRS 2014
- Fundamental
- Price
- NOTE $0.69
- CHRS $0.90
- Analyst Decision
- NOTE Strong Buy
- CHRS Buy
- Analyst Count
- NOTE 6
- CHRS 3
- Target Price
- NOTE $2.63
- CHRS $4.68
- AVG Volume (30 Days)
- NOTE 3.4M
- CHRS 1.2M
- Earning Date
- NOTE 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- NOTE N/A
- CHRS N/A
- EPS Growth
- NOTE N/A
- CHRS N/A
- EPS
- NOTE N/A
- CHRS N/A
- Revenue
- NOTE $115,665,000.00
- CHRS $272,251,000.00
- Revenue This Year
- NOTE N/A
- CHRS N/A
- Revenue Next Year
- NOTE $41.14
- CHRS $106.56
- P/E Ratio
- NOTE N/A
- CHRS N/A
- Revenue Growth
- NOTE N/A
- CHRS 19.87
- 52 Week Low
- NOTE $0.48
- CHRS $0.66
- 52 Week High
- NOTE $2.07
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NOTE 61.52
- CHRS 59.04
- Support Level
- NOTE $0.66
- CHRS $0.73
- Resistance Level
- NOTE $0.84
- CHRS $0.82
- Average True Range (ATR)
- NOTE 0.07
- CHRS 0.04
- MACD
- NOTE 0.03
- CHRS 0.02
- Stochastic Oscillator
- NOTE 68.32
- CHRS 88.02
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.